Hagens Berman Issues Deadline Alert for Corcept Therapeutics Investors in Fraud Lawsuit
On April 21, 2026, Hagens Berman, a law firm known for defending shareholder rights, has issued a reminder to investors of Corcept Therapeutics Incorporated (NASDAQ: CORT) regarding an imperative lead plaintiff deadline in a pending securities fraud class action lawsuit. This alert is aimed at investors who have faced substantial financial losses during a specific time frame from October 31, 2024, to December 30, 2025, known as the "Class Period".
The legal case, identified as Allegheny Cnty. Empl. Ret. Sys. v. Corcept Therapeutics Inc., et al., bears the case number 26-cv-01525 in the Northern District of California. The deadline for investors to petition the court to be appointed as Lead Plaintiff is set for April 21, 2026.
The primary focus of the class action revolves around claims that Corcept Therapeutics misled investors concerning its lead drug candidate, relacorilant, especially in light of communications with the FDA. Allegations suggest that while the company publicly projected confidence in the drug's approval prospects, it failed to disclose crucial warnings issued by the FDA about the inadequacy of their clinical data.
During pre-submission meetings in 2024 and 2025, the FDA voiced explicit concerns regarding the efficacy evidence presented by Corcept, establishing a context of misrepresentation that investors may have unwittingly relied upon.
Despite knowing the grave concerns from the FDA, it's alleged that Corcept continued to promote its Phase 3 trial results as if they were reliable, which only deepens the alleged information gap.
The situation escalated dramatically on December 31, 2025, when Corcept disclosed it had received a Complete Response Letter (CRL) from the FDA. This letter indicated that the agency was unable to reach a positive benefit-risk assessment for relacorilant due to insufficient evidence. Consequently, Corcept's stock price collapsed from $70.20 at the close of trading on December 30, 2025, to $34.80 by the next trading day, wiping out nearly $2.5 billion in market capitalization overnight.
As noted by Reed Kathrein, the Hagens Berman partner steering the investigation, this scenario epitomizes a classic information gap. The firm's findings suggest that although Corcept’s leadership had been warned of potential setbacks, they portrayed an optimistic picture to investors, arguably leading to misinformed investment decisions.
For affected investors, Hagens Berman encourages those who purchased Corcept stock during the aforementioned period to submit their losses ahead of the approaching deadline. Detailed information regarding the case, including how to submit such claims, is available through Hagens Berman's dedicated CORPT Case Page.
In addition to guiding lead plaintiffs, Hagens Berman emphasizes the importance of whistleblowers in these investigations. Individuals with non-public insights about Corcept Therapeutics may have opportunities to assist in the ongoing inquiries or benefit from the SEC Whistleblower program, which offers financial rewards for original information leading to successful enforcement actions by the SEC.
Hagens Berman is globally recognized for its commitment to holding corporations accountable for their misdeeds and advocating for the rights of investors and consumers. The firm has a noteworthy record of recovering over $2.9 billion for parties adversely impacted by corporate negligence. Further details about the firm's mission and successes can be accessed via their website, where updates regarding legal cases and actions are also shared through social media platforms.
The legal case, identified as Allegheny Cnty. Empl. Ret. Sys. v. Corcept Therapeutics Inc., et al., bears the case number 26-cv-01525 in the Northern District of California. The deadline for investors to petition the court to be appointed as Lead Plaintiff is set for April 21, 2026.
Summary of Allegations
The primary focus of the class action revolves around claims that Corcept Therapeutics misled investors concerning its lead drug candidate, relacorilant, especially in light of communications with the FDA. Allegations suggest that while the company publicly projected confidence in the drug's approval prospects, it failed to disclose crucial warnings issued by the FDA about the inadequacy of their clinical data.
Repeated FDA Warnings
During pre-submission meetings in 2024 and 2025, the FDA voiced explicit concerns regarding the efficacy evidence presented by Corcept, establishing a context of misrepresentation that investors may have unwittingly relied upon.
Flawed Data Narrative
Despite knowing the grave concerns from the FDA, it's alleged that Corcept continued to promote its Phase 3 trial results as if they were reliable, which only deepens the alleged information gap.
The CRL Bombshell
The situation escalated dramatically on December 31, 2025, when Corcept disclosed it had received a Complete Response Letter (CRL) from the FDA. This letter indicated that the agency was unable to reach a positive benefit-risk assessment for relacorilant due to insufficient evidence. Consequently, Corcept's stock price collapsed from $70.20 at the close of trading on December 30, 2025, to $34.80 by the next trading day, wiping out nearly $2.5 billion in market capitalization overnight.
As noted by Reed Kathrein, the Hagens Berman partner steering the investigation, this scenario epitomizes a classic information gap. The firm's findings suggest that although Corcept’s leadership had been warned of potential setbacks, they portrayed an optimistic picture to investors, arguably leading to misinformed investment decisions.
For affected investors, Hagens Berman encourages those who purchased Corcept stock during the aforementioned period to submit their losses ahead of the approaching deadline. Detailed information regarding the case, including how to submit such claims, is available through Hagens Berman's dedicated CORPT Case Page.
Whistleblower Opportunities
In addition to guiding lead plaintiffs, Hagens Berman emphasizes the importance of whistleblowers in these investigations. Individuals with non-public insights about Corcept Therapeutics may have opportunities to assist in the ongoing inquiries or benefit from the SEC Whistleblower program, which offers financial rewards for original information leading to successful enforcement actions by the SEC.
About Hagens Berman
Hagens Berman is globally recognized for its commitment to holding corporations accountable for their misdeeds and advocating for the rights of investors and consumers. The firm has a noteworthy record of recovering over $2.9 billion for parties adversely impacted by corporate negligence. Further details about the firm's mission and successes can be accessed via their website, where updates regarding legal cases and actions are also shared through social media platforms.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.